Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Beam Therapeutics Inc. (BEAM) vs Harmony Biosciences Holdings, Inc. (HRMY)

Beam Therapeutics Inc. and Harmony Biosciences Holdings, Inc. are both Biotechnology companies. Beam Therapeutics Inc. and Harmony Biosciences Holdings, Inc. are of similar size ($2.6B and $2.4B). Beam Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Harmony Biosciences Holdings, Inc. trades at 13.2×. Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against 24.3%. Harmony Biosciences Holdings, Inc. has the higher net margin (18.9% vs −55.5%) and the higher return on invested capital (29.7% vs −1,599.3%). Across the 18 metrics below, Harmony Biosciences Holdings, Inc. leads on 11 and Beam Therapeutics Inc. on 7.

Valuation

Metric BEAM HRMY Biotechnology median
P/E n/m 13.18 7.88
P/S 16.23 2.49 11.47
P/B 2.37 2.39 2.52
Price to free cash flow n/m 7.59 21.16
EV/EBITDA n/m 7.35 0.74
EV/Sales 9.48 1.95 10.73
Earnings yield (3.38%) 7.59% (28.84%)
Free cash flow yield (14.72%) 13.17% (23.03%)

Profitability

Metric BEAM HRMY Biotechnology median
Gross margin 100.00% 75.42% 65.16%
Operating margin (242.27%) 24.03% 0.00%
Net margin (55.45%) 18.88% 0.00%
Free cash flow margin (238.90%) 36.99% 0.00%
Return on equity (8.18%) 20.46% (57.72%)
Return on assets (6.23%) 14.61% (49.22%)
Return on invested capital (1,599.30%) 29.70% 0.00%

Growth

Metric BEAM HRMY Biotechnology median
Revenue growth (TTM) 158.88% 24.25% 5.64%
EPS growth (last fiscal year) 82.31% 7.97% —
Revenue growth, 5-year CAGR 466.27% 40.30% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM HRMY Biotechnology median
Debt to equity 0.09 0.15 0.00
Current ratio 14.57 3.48 4.73
Net debt to EBITDA 3.30 (2.63) 0.96

Dividend

Metric BEAM HRMY Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BEAM HRMY Biotechnology median
Market cap 2.55b 2.40b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack